RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
HLB Life Science Co Stock

HLB Life Science Co P/E 2025

HLB Life Science Co P/E

-199.8

Ticker

067630.KQ

ISIN

KR7067630004

As of Jan 20, 2025, HLB Life Science Co's P/E ratio was -199.8, a 620.52% change from the -27.73 P/E ratio recorded in the previous year.

The HLB Life Science Co P/E history

HLB Life Science Co Aktienanalyse

What does HLB Life Science Co do?

HLB Life Science Co., Ltd. is a leading company in the research, development, and production of biotechnological and pharmaceutical products. The company was founded in 2015 in Seoul, South Korea. Due to the founders' extensive experience in the field of life science and biotechnology, HLB Life Science has quickly established itself as a key player in the industry. HLB Life Science's business model is based on the development and production of innovative biotechnological and pharmaceutical products, as well as collaboration with other companies and research institutions. The aim is to improve people's quality of life by providing effective and safe medications and therapies. The company is divided into various divisions. The Biopharmaceuticals division includes the development and production of biotechnological products such as antibodies, proteins, vaccines, and diagnostics. The Pharmaceuticals division develops and produces advanced drugs in the field of oncology, immunology, and neurology. The Clinical Research Services division offers contract research services in the field of clinical studies to test the effectiveness and safety of drugs. In addition, HLB Life Science Co., Ltd. is also active in the Nutra-Pharmaceuticals division, specializing in the development and production of dietary supplements. HLB Life Science offers various products tailored to the needs of patients. In the field of Biopharmaceuticals, for example, the company produces antibodies and proteins for the treatment of cancer, inflammatory diseases, and infections. Another innovative product is a fully humanized antibody against the hepatitis B virus, which is one of the most common liver diseases. In the Pharmaceuticals field, HLB Life Science offers innovative drugs for the treatment of cancer, autoimmune diseases, and neurological disorders. In the Nutra-Pharmaceuticals field, the company offers dietary supplements based on natural ingredients that can strengthen the immune system. HLB Life Science Co., Ltd. is known in the industry for its innovative strength and excellent research results. The company places great emphasis on continuous research and development to develop innovative products and continuously improve existing products. Due to their outstanding products and services, HLB Life Science has already exported to various countries worldwide and has thus played a significant role in the global market. Looking to the future, HLB Life Science Co., Ltd. continues to focus on innovative research and development, as well as close collaboration with universities and research institutions. The company aims to improve people's health and well-being through effective and safe medications and therapies. HLB Life Science Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering HLB Life Science Co's P/E Ratio

The Price to Earnings (P/E) Ratio of HLB Life Science Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing HLB Life Science Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of HLB Life Science Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in HLB Life Science Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about HLB Life Science Co stock

What is the price-to-earnings ratio of HLB Life Science Co?

The price-earnings ratio of HLB Life Science Co is currently -199.8.

How has the price-earnings ratio of HLB Life Science Co changed compared to last year?

The price-to-earnings ratio of HLB Life Science Co has increased by 620.52% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of HLB Life Science Co high compared to other companies?

Yes, the price-to-earnings ratio of HLB Life Science Co is high compared to other companies.

How does an increase in the price-earnings ratio of HLB Life Science Co affect the company?

An increase in the price-earnings ratio of HLB Life Science Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of HLB Life Science Co affect the company?

A decrease in the price-earnings ratio of HLB Life Science Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of HLB Life Science Co?

Some factors that influence the price-earnings ratio of HLB Life Science Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does HLB Life Science Co pay?

Over the past 12 months, HLB Life Science Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HLB Life Science Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of HLB Life Science Co?

The current dividend yield of HLB Life Science Co is .

When does HLB Life Science Co pay dividends?

HLB Life Science Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of HLB Life Science Co?

HLB Life Science Co paid dividends every year for the past 0 years.

What is the dividend of HLB Life Science Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is HLB Life Science Co located?

HLB Life Science Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von HLB Life Science Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HLB Life Science Co from 1/20/2025 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 1/20/2025.

When did HLB Life Science Co pay the last dividend?

The last dividend was paid out on 1/20/2025.

What was the dividend of HLB Life Science Co in the year 2024?

In the year 2024, HLB Life Science Co distributed 0 KRW as dividends.

In which currency does HLB Life Science Co pay out the dividend?

The dividends of HLB Life Science Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von HLB Life Science Co

Our stock analysis for HLB Life Science Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Life Science Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.